Key result
Protocol outlines systematic review of CV risk factors in heterozygous familial hypercholesterolemia.
Systematic Review
Answers are grounded in this paper and cite their sources.
Systematic review protocol details methods to identify cardiovascular event predictors in heterozygous familial hypercholesterolaemia, highlighting opportunities to improve clinical prevention.
INTRODUCTION: Heterozygous familial hypercholesterolaemia (heFH) is the most common monogenic cause of premature atherosclerotic cardiovascular disease. The precise diagnosis of heFH is established by genetic testing. This systematic review will investigate the risk factors that predict cardiovascular events in patients with a genetic diagnosis of heFH. METHODS AND ANALYSIS: Our literature search will cover publications from database inception until June 2023. We will undertake a search of CINAHL (trial), clinicalKey, Cochrane Library, DynaMed, Embase, Espacenet, Experiments (trial), Fisterra, ÍnDICEs CSIC, LILACS, LISTA, Medline, Micromedex, NEJM Resident 360, OpenDissertations, PEDro, Trip Database, PubPsych, Scopus, TESEO, UpToDate, Web of Science and the grey literature for eligible studies. We will screen the title, abstract and full-text papers for potential inclusion and assess the risk of bias. We will employ the Cochrane tool for randomised controlled trials and non-randomised clinical studies and the Newcastle-Ottawa Scale for assessing the risk of bias in observational studies. We will include full-text peer-reviewed publications, reports of a cohort/registry, case-control and cross-sectional studies, case report/series and surveys related to adults (≥18 years of age) with a genetic diagnostic heFH. The language of the searched studies will be restricted to English or Spanish. The Grading of Recommendations, Assessment, Development and Evaluation approach will be used to assess the quality of the evidence. Based on the data available, the authors will determine whether the data can be pooled in meta-analyses. ETHICS AND DISSEMINATION: All data will be extracted from published literature. Hence, ethical approval and patient informed consent are not required. The findings of the systematic review will be submitted for publication in a peer-reviewed journal and presentation at international conferences. PROSPERO REGISTRATION NUMBER: CRD42022304273.
No takes yet. Share an insight, caveat, or question.
Mansilla-Rodríguez et al. (2023) conducted a systematic review in Heterozygous familial hypercholesterolaemia. Risk factors for cardiovascular events was evaluated on Cardiovascular events. This systematic review protocol was designed to evaluate risk factors for cardiovascular events in adults with heterozygous familial hypercholesterolaemia, and currently reports no results.
Synapse has enriched 10 related papers. Consider them for comparative context: